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Several drug-metabolizing enzymes, preferentially expressed in the liver, have the potential to act as minor
histocompatibility antigens. In the present study, we analyzed the impact of glutathione S-transferase T1
(GSTT1), glutathione S-transferase M1, glutathione S-transferase P1, and UDP glucuronosyl transferase 2B17
(UGT2B17) disparities on the outcome of 125 patients undergoing allogeneic hematopoietic stem cell
transplantation. Grades 2 to 4 acute graft-versus-host disease (aGVHD) developed in 56.2% versus 73.3% of
GSTT1-matched versus mismatched patients (P ¼ .048). Remarkably, 8.6% GSTT1-matched patients developed
grades 2 to 4 liver aGVHD, compared with 36.8% among GSTT1-mismatched recipients (P < .001). Regarding
chronic graft-versus-host disease (cGVHD), 34.8% versus 70.7% matched versus mismatched patients devel-
oped overall cGVHD (P ¼ .038) and 16.3% versus 48% developed hepatic cGVHD (P ¼ .006). We also found a
strong association between the UGT2B17 mismatch and the risk of severe aGVHD (P ¼ .001), especially with
gut involvement (P < .001). Most striking was the inﬂuence of the GSTT1 mismatch on nonrelapse mortality
(26.8% versus 52.6%, P ¼ .031) and overall survival (62% versus 36.9%, P ¼ .045). In summary, UGT2B17 and
GSTT1 mismatch are risk factors for the development of GVHD and the latter also inﬂuences on mortality and
survival after allogeneic transplantation from HLA-identical donors.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Graft-versus-host disease (GVHD) remains the main
cause of morbidity and mortality after allogeneic trans-
plantation. Even after allogeneic hematopoietic stem cell
transplantation (allo-HSCT) from HLA-identical donors, its
incidence varies from 25% to 40% and from 30% to 60% for
acute GVHD (aGVHD) and chronic GVHD (cGVHD), respec-
tively. In the HLA-matched transplantation setting, GVHD is,
at least in part, attributed to the presence of minor histo-
compatibility antigens (miHA) disparities, which might
trigger the immune response of donor T lymphocytes [1].edgments on page 1361.
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14.05.008Remarkably, some of these miHA may be preferentially
expressed in speciﬁc organs so that when they are
restricted to the hematopoietic tissue, they might favor the
graft-versus-leukemia effect [2]. Nevertheless, most of them
are ubiquitously expressed and play an important role in the
development of GVHD [3-5].
More than 30 polymorphic antigens have been identiﬁed,
including antigens encoded either by genes on the Y chro-
mosome (H-Y antigens) [6-9] or on autosomal chromosomes
[10]. Comparative DNA analyses have revealed 2 main types
of polymorphism: single nucleotide variants and gene
deletions.
Several drug-metabolizing enzymes belonging to the
glutathioneS-transferase familyhave thepotential to behave as
miHA. Among them, glutathione S-transferase M1 (GSTM1)
andglutathioneS-transferaseT1 (GSTT1)present thenull allele,
meaning the absence of protein due to gene deletions [11],
whereas the allelic variants of humanglutathione S-transferase
P1 (GSTP1) differ in 1 amino acid in position 104 (isoleucine or
valine), themost frequentbeing Ile in theCaucasianpopulation:
Ile/Ile (42-65%), Ile/Val (35%), and Val/Val (10%) [12].Transplantation.
Table 1
Baseline Characteristics of Patients (n ¼ 125)
Characteristics Patients (n ¼ 125) %
Recipient age, median (range), yr 37 (2-65)
Donor age, median (range), yr 35 (3-64)
Donor/recipient gender
Male/male 37
Male/female 34
Female/female 25
Female/male 28
Unknown/male 1
Diagnosis
AML 43 34.4
CML 6 4.8
ALL 30 24
CLL 1 .8
MDS 12 9.6
HD 10 8
NHL 11 8.8
Others 12 9.6
Donor
Related 96 76.8
Unrelated 29 23.2
Conditioning regimen
First transplantation
RIC 74 59.2
Myeloablative 51 40.8
Second transplantation
RIC 8 72.73
Myeloablative 3 27.27
Source of stem cell
Peripheral blood 113 90.4
Bone marrow 12 9.6
Prophylaxis of GVHD
Cyclosporine 15 12
Cyclosporine plus methotrexate 95 76
Cyclosporine plus mycophenolate mofetil 14 11.2
Others 1 .8
AML indicates acute myeloid leukemia; CML, chronic myeloid leukemia;
ALL, acute lymphoid leukemia; CLL, chronic lymphoid leukemia; MDS,
myelodysplastic syndrome; HD, Hodgkin’s disease; NHL, non-Hodgkin
lymphoma; RIC, reduced-intensity conditioning.
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erythrocytes, and is absent in a homozygous manner in 20%
of the Caucasian population [11]. Immune recognition of the
GSTT1 alloantigen, with production of donor speciﬁc
antibodies (Abs), has already been described in GSTT1-null
recipients receiving liver and kidney transplants from
GSTT1-positive donors. These Abs constitute a risk factor
to develop de novo immune hepatitis [13] or chronic
antibody-mediated rejection [14]. In addition, we have
previously described that the presence of these Abs may
induce hepatic GVHD in GSTT1-positive patients who receive
allo-HSCT from GSTT1-null donors [15,16].
On the other hand, GSTM1 is mainly expressed in
hepatocytes, erythrocytes, and the parathyroid gland, and
homozygous deletion of the gene is present in 50% of the
Caucasian population [17].
Finally, enzymes involved in sex steroid metabolism may
also behave as miHA, such as the protein UDP glucuronosyl
transferase 2B17 (UGT2B17). In this regard, UGT2B17 has
been previously described as a risk factor for GVHD among
UGT2B17-mismatched patients [18,19], as well as in
UGT2B17-positive recipients [20]. This protein is absent
in 12% of Caucasian population and it is highly expressed in
prostatic, gastrointestinal, and hepatic tissues.
The aim of this study was to explore the impact of the
donor-recipient mismatch in these 4 drug-metabolizing en-
zymes, GSTT1, GSTM1, GSTP1, and UGT2B17, on the incidence
of organ-speciﬁc (gastrointestinal, cutaneous, and hepatic)
GVHD and on the outcome of patients undergoing allo-HSCT.
PATIENTS AND METHODS
Patients
The retrospective study group included 125 patients who underwent
allo-HSCT from an HLA-identical donor between January 2003 and May
2011 at the Hospital Universitario Virgen del Rocio, Sevilla. Informed
consent was obtained from each patient and donor according to institutional
guidelines. The procedures were in accordance with the Helsinki
Declaration. When the donor was related, the genotypes of each allele at the
HLA-A, B, C, and DRB1 loci were determined by low-resolution DNA typing.
In the cases of unrelated donors, the genotypes were determined by
high-resolution DNA typing (HLA-A, -B, -C, -DRB1, -DQB1, -DPB1).
Diagnostic Criteria
Acute and cGVHD were graded according to standard criteria [21,22], as
well as according to the National Institutes of Health (NIH) classiﬁcation for
cGVHD [23]. Among the 24 patients diagnosed with liver aGVHD, 8 did not
have a conﬁrmatory biopsy, whereas 16 had histological conﬁrmation of
GVHD either on liver and/or in other target organ (1 liver, 10 gastrointestinal
tract, and 5 skin). All of them displayed biochemical abnormalities with
increased bilirubin and/or transaminases. As far as cGVHD is concerned, 6 of
24 patients diagnosed with hepatic cGVHD underwent liver biopsy, 3 had
gastrointestinal biopsies, and 10 had skin biopsies, whereas 6 did not have
available biopsies. The latter patients were diagnosed based on the presence
of conﬁrmatory signs of cGVHD in other target organs, according to NIH,
together with the presence of abnormal liver function tests, once other
causes, such as viral infection or iron overload, were ruled out.
Regarding gastrointestinal diagnoses, aGVHD occurred in 36 patients. Of
these, 21 patients had biopsy-proven diagnoses and the remaining patients
were diagnosed based on the presence of signs and/or symptoms of
gastrointestinal involvement, together with involvement of another target
organ. Forty-ﬁve patients were diagnosed with gastrointestinal cGVHD; 16
had intestinal biopsies available, whereas 14 presented with symptoms
suggestive of gastrointestinal involvement together with conﬁrmatory
skin biopsies. Finally, 15 did not have biopsies available but displayed
conﬁrmatory signs in other target organs, according to NIH.
GSTT1, UGT2B17, GSTM1, and GSTP1 Genotyping
Pretransplantation peripheral blood samples from the patients and their
donors were collected. Genomic DNA was puriﬁed using the QIAmp DNA
mini kit (Quiagen, Hilden, Germany) according to the manufacturer’s
protocol. For the PCR, the GSTT1 forward primer was 50-TTC CTT ACT GGT
CCT CAC ATC TC-30 , and the GSTT1 reverse primer was 50-TCA CCG GAT CATGGC CAG CA-30 . We used the KRAS gene as internal control of the reaction
(forward primer: 50-GTA CTG GTG GAG TAT TTG ATA GTG-3’and reverse
primer: 50-TAG CTG TAT CGT CAAGGC AC-30 . The PCR program startedwith a
5-minute denaturalization step at 94C, followed by 40 cycles with 3 steps/
cycle; 30 seconds at 94C, 45 seconds at 58C, and 1 minute at 72C. The
ﬁnal extension consisted of 5 minutes at 72C. The products were analyzed
by 2% agarose gel electrophoresis. The expected band sizes were
498 base pairs for GSTT1 and 110 base pairs for the internal control. GSTM1
genotypes were determined under the same PCR conditions as GSTT1,
using sense primer 50-GAGATGAAGTCCTTCAGA-30 and antisense primer 50-
GCTTCACGTGTTATGGAGGTT-30 , with the same internal control of the reac-
tion. The expected GSTM1 band sizes were 150 base pairs. Genotyping of the
UGT2B17 alleleswas performed as described by Lazarous et al. [24] and GSTP1
genotyping was determined as previously published by Harries et al. [25]Statistical Analysis
For this analysis, we categorized a donor/recipient pair as mismatched
when the recipient was positive for the antigen (GSTT1, UGT2B17, or GSTM1)
and the donor was negative. Otherwise, the pair was considered to be
matched. In the case of GSTP1, the mismatch was deﬁned as the presence in
the recipient of an allele that is absent in the donor and, therefore, can be
recognized as foreign by donor lymphocytes. Other variables included in the
analysis were the type of the donor (sibling and unrelated), recipient/donor
sex, and GVHD prophylaxis. Events were calculated from the time of
transplantation as follows: overall survival (OS) was calculated from trans-
plantation until death from any cause, and surviving patients were censored
at last follow-up. Patients who showed evidence of engraftment could be
evaluated for aGVHD, whereas patients who engrafted and survived more
than 100 days could be evaluated for cGVHD. For both aGVHD and cGVHD,
the day of onset was analyzed as the time to event in evaluable patients.
Comparison of GVHD between groups was performed using the
Gray Test [26]. The cumulative incidence was computed with the
cmprsk package for R 2.14.0 software (R Development Core Team, 2011;
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the event of interest as the competing event. OS was estimated with the
Kaplan-Meier method, and groups were compared with the log-rank test
using the statistical software SPSS version 13.0 (SPSS Inc, Chicago, IL). Cox
regression model was used for multivariate analysis, including all variables
with a P value<.20 in univariate analysis. Acute and cGVHDwere considered
as time-dependent covariates. T-tailed P values <.05 were considered
statistically signiﬁcant.
RESULTS
Patients’ Characteristics
The characteristics of the patients and donors are sum-
marized in Table 1. The median follow-up was 45 months
(range, .6 to 256 months).
Regarding miHA status, 20 patients (16%) had the GSTM1
mismatch, 32 patients (25.6%) the GSTP1 mismatch, 13
patients (10.4%) the UGT2B17 mismatch, and 19 patients
(15.2%) the GSTT1 mismatch. Fourteen of them (11.2%),
shared 2 mismatches and only 1 (.8%) had 3 mismatches. The
proportion of mismatches was higher in the transplantations
from unrelated donors. In total, there were 96 trans-
plantations from siblings and 29 from unrelated donors. The
percentages of mismatches for siblings and unrelated donors
were as follows: GSTT1: 12.5% versus 24.14%, respectively;
GSTM1: 13.54% versus 24.14%, respectively; GSTP1: 22.92%
versus 34.48%, respectively; and UGT2B17: 9.38% versus
13.79%, respectively. Nevertheless, having an unrelated
donor, analyzed as an independent variable, did not confer a
higher risk of developing GVHD in our study.
Risk Factors for Developing Acute GVHD
As far as the risk of grades 2 to 4 aGVHD is concerned, we
found that UGT2B17 mismatch was related to an increased
risk of both gut and skin aGVHD. In this regard, cumulative
incidence of grades 2 to 4 gut aGVHD was 15.6% among
UGT2B17-matched patients, compared with 46.2% among
UGT2B17-mismatched patients (P ¼ .007). In addition, 50.5%
of UGT2B17-matched patients were diagnosed with grades 2
to 4 skin aGVHD versus 76.9% of UGT2B17-mismatched
patients (P ¼ .048) (Table 2).
On the other hand, GSTT1 mismatch was also a risk factor
for developing overall, skin, and hepatic grades 2 to 4 aGVHD.
Accordingly, 56.2% versus 73.3% of GSTT1-matched versus
mismatched patients developed grades 2 to 4 aGVHD
(P ¼ .048) (Table 2, Figure 1A). Regarding speciﬁc organ
involvement, 49.5% of GSTT1-matched patients were
diagnosed with grades 2 to 4 skin aGVHD, compared with
67.4% of GSTT1-mismatched recipients. Finally, 8.6% of
GSTT1-matched patients developed grades 2 to 4 liverTable 2
Inﬂuence of miHA Mismatches on the Development of aGVHD
Grades 2-4
aGVHD
GSTT1 (n ¼ 19)
n ¼ 125 Matched, % Mismatched, % P Val
Overall (CI) 56.2 (47.4-66.6) 73.7 (55.6-97.6) .048
Skin (CI) 49.5 (40.8-60.1) 67.4 (49.8-94.1) .036
Gastrointestinal (CI) 19 (12.8-28.3) 21.1 (8.6-51.6) .721
Liver (CI) 8.6 (4.6-16.1) 36.8 (20-67.7) 8  1
grades 3-4
aGVHD
GSTT1 (n ¼ 19)
n ¼ 125 Matched, % Mismatched, % P
Overall (CI) 20 (13.6-29.4) 47.4 (28.9-77.5) .004
Skin (CI) 18.1 (12-27.2) 26.3 (12.1-57.3) .356
Gastrointestinal (CI) 4.8 (2-11.3) 15.8 (5.4-46) .069
Liver (CI) 3.8 (1.5-10) 36.8 (20-67.7) 3.02
CI indicates cumulative incidence.aGVHD, compared with 36.8% of GSTT1-mismatched
recipients (P < .001) (Table 2, Figure 1C).
GSTM1- and GSTP1-mismatch status were not risk factors
for developing either overall or organ-speciﬁc grades 2 to 4
GVHD. Concerning the risk of grades 3 to 4 aGVHD, the
cumulative incidence was 20.2% versus 61.5% for patients
matched versus mismatched for the UGT2B17 alleles
(P ¼ .001). Upon analyzing speciﬁc organ involvement,
UGT2B17 disparity increased the risk of grades 3 and 4
skin aGVHD, with a cumulative incidence of 15.6% versus
53.8% for matched versus mismatched pairs, respectively
(P ¼ .001). More striking was the impact of UGT2B17
disparity on the risk of severe gut aGVHD. In this regard, 2.8%
matched versus 38.5% mismatched patients developed
grades 3 and 4 gut aGVHD (P < .001) (Table 2).
Finally, GSTT1 mismatch increased risk of grades 3 to 4
aGVHD, with 20% versus 47.4% cumulative incidence for
matched versus mismatched pairs, respectively (P ¼ .004)
(Table 2, Figure 1B). The impact of the GSTT1 mismatch
was highly signiﬁcant on the development of grades 3 and
4 liver aGVHD, with a cumulative incidence of 3.8%
for GSTT1-matched versus 36.8% for GSTT1-mismatched
patients (P < .001) (Table 2, Figure 1D).
In multivariate analysis, GSTT1 mismatch signiﬁcantly
increased the risk of hepatic aGVHD, with a hazard ratio (HR)
of 2.66 (95% conﬁdence interval [CI], 1.06 to 6.67; P ¼ .037)
(data not shown).Risk Factors for Developing Chronic GVHD
One hundred and eleven patients with more than
100 days of follow-up after transplantation were analyzed.
Among them, 19 (17.12%) patients were GSTM1 mismatched,
28 (25.23%) were GSTP1 mismatched, 15 (13.51%) were
GSTT1 mismatched, and 8 (7.21%) patients were UGT2B17
mismatched. As shown in Table 3, the GSTT1 mismatch
signiﬁcantly increased the risk of overall cGVHD, with a cu-
mulative incidence of 34.8% versus 70.7% among patients
receiving transplantations frommatched versus mismatched
donors (P ¼ .038) (Figure 2A). Remarkably, when we
separately analyzed organ involvement, again, patients with
GSTT1 mismatch had a higher risk of liver cGVHD: 16.3%
compared with 48% for matched versus mismatched pairs
(P¼ .006) (Figure 2B). Mismatches for the othermiHA did not
inﬂuence the risk of cGVHD.
In a multivariate analysis, prior aGVHD (HR, 2.56; 95% CI,
1.13 to 5.83; P¼ .025) and GSTT1mismatch (HR, 2.42; 95% CI,
1.1 to 5.31; P¼ .027) signiﬁcantly increased risk of cGVHD. AsUGT2B17 (n ¼ 13)
ue Matched, % Mismatched, % P Value
56.9 (48.3-67) 76.9 (56-100) .166
50.5 (41.9-60.8) 76.9 (56-100) .048
15.6 (10.1-24.2) 46.2 (24.8-86) .007
04 11.9 (7.1-19.9) 23.1 (8.2-65.1) .23
UGT2B17 (n ¼ 13)
Matched, % Mismatched, % P
20.2 (13.9-29.4) 61.5 (39-97.1) .001
15.6 (10.1-24.2) 53.8 (31.6-91.9) .001
2.8 (.9-8.4) 38.5 (18.6-79.7) 1.19  106
 106 7.3 (3.8-14.3) 23.1 (8.2-65.1) .052
Figure 1. GSTT1 disparity is a risk factor for acute GVHD. This ﬁgure illustrates the cumulative incidence of different events between GSTT1-mismatched versus
GSTT1-matched recipients. In all the cases, the differences are statistically signiﬁcant: (A) grades 2 to 4 acute GVHD (P ¼ .048); (B) grades 3 to 4 acute GVHD
(P ¼ .004); (C) grades 2 to 4 liver acute GVHD (<.001); and (D) grades 3 to 4 liver acute GVHD (P < .001).
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4.89; 95% CI, 1.17 to 20.32; P¼ .029) and GSTT1 disparity (HR,
5.32; 95% CI, 1.78 to 15.92; P ¼ .003) were related to higher
risk of developing hepatic cGVHD.Table 3
Impact of Different miHA Mismatches on the Incidence of cGVHD
cGVHD GSTT1 (n ¼ 15)
n ¼ 111 Matched, % Mismatched, % P
Overall (CI) 34.8 (26.2-46.2) 70.7 (47.4-100) .
Extensive (CI) 23.9 (16.6-34.6) 56 (33.4-93.3) .
Skin (CI) 22.5 (15.2-33.3) 41.9 (21.7-80.9) .
Gastrointestinal (CI) 11.9 (6.8-20.9) 20 (7-57.2) .
Liver (CI) 16.3 (10.2-26) 48 (26.9-85.6) .
CI indicates cumulative incidence.Impact of miHA-mismatch on Survival
Nonrelapse mortality (NRM) after 3 years was 26.8% for
GSTT1-matched versus 52.6% for GSTT1-mismatched re-
cipients (P ¼ .031) (Table 4, Figure 3A). OS at 3 years was 62%UGT2B17 (n ¼ 8)
Value Matched, % Mismatched, % P Value
038 38.1 (29.4-49.3) 62.5 (34.2-100) .288
060 25.8 (18.3-36.4) 62.5 (34.2-100) .072
239 23.2 (16-33.7) 56.2 (26.9-100) .112
339 12.1 (7.1-20.6) 25 (6.8-91.8) .499
006 19.4 (12.9-29.2) 41.7 (15.9-100) .237
Figure 2. GSTT1 disparity is a risk factor for chronic GVHD. This ﬁgure shows the cumulative incidence of (A) chronic GVHD between GSTT1-mismatched versus
GSTT1-matched recipients (P ¼ .038) and (B) chronic GVHD in its liver presentation (P ¼ .006).
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(P ¼ .045) (Table 4, Figure 3B). We did not observe any in-
ﬂuence on survival regarding GSTM1-, GSTP1-, or UGT2B17-
mismatch status.
In addition, in multivariate analysis, development of
aGVHD and GVHD prophylaxis with cyclosporine plus
mycophenolate mofetil signiﬁcantly inﬂuenced NRM (HR,
4.22; 95% CI, 1.65 to 10.78; P ¼ .003 and HR, 3.83; 95% CI, 1.5
to 9.8; P ¼ .005, respectively) as well as OS (HR, 2.88; 95% CI,
1.31 to 6.35; P ¼ .008 and HR, 3.02; 95% CI, 1.38 to 6.61; P ¼
.006, respectively) (data not shown).
DISCUSSION
Previous studies have described the impact of miHA
mismatching on the occurrence of GVHD after HLA-matched
HSCT [20,27]. In the current study, we focused on the analysis
of 4 potential miHA and their inﬂuence on the development
of organ-speciﬁc aGVHD and cGVHD. More speciﬁcally, we
studied drug- and hormone-metabolizing enzymes encoded
by genes whose allelic variants are either related to single
nucleotide polymorphisms or to gene deletions.
Considering that some of these genes are absent in a
signiﬁcant proportion of the Caucasian population, we
focused on the effects of GSTT1, GSTM1, GSTP1, and UGT2B17
disparities on outcome among patients undergoing trans-
plantation from HLA-identical donors. These miHA are
mainly expressed in speciﬁc organs, and this property alsoTable 4
NRM, Disease-Free Survival, and OS Results
n ¼ 125 GSTT1
Matched, % Mismatched, % P Valu
NRM (CI) 26.8 (19.3-37.2) 52.6 (32-86.3) .031
DFS 59.6 36.9 .109
OS 62 36.9 .045
CI indicates cumulative incidence; DFS, disease-free survival.
This table shows that both GSTT1 mismatch (P ¼ .031) and UGT2B17 mismatch (P
signiﬁcant when patients are GSTT1 mismatched with their donors (P ¼ .045).allowed us to explore whether or not this preferential
expression may, in turn, increase the risk of GVHD, specif-
ically in those organs. We found that GSTT1 disparity
increased the risk of developing both overall aGVHD and
cGVHD but, interestingly, differences between matched and
mismatched patients were remarkable regarding liver
involvement. Similarly, UGT2B17 mismatch increased the
risk of overall aGVHD and, although it also inﬂuenced skin
GVHD, differences were highly signiﬁcant regarding gut
involvement. McCarroll et al. found a correlation between
UGT2B17 mismatch and GVHD, but not with GSTM1, in 2
cohorts of patients from United States’ and Finnish pop-
ulations, which is consistent with our results [20]. However,
upon analyzing the inﬂuence of the GSTT1 mismatch on
outcomes, they did not ﬁnd any association with either
aGVHD or chronic GVHD. Considering that the frequency of
the GSTT1 null genotype greatly varies among ethnic pop-
ulations [11], it might account for the differences observed
between these studies.
We have previously shown that GSTT1 mismatch may
elicit a speciﬁc antibody response after allogeneic stem cell
transplantation in cases where donors were previously
primed through pregnancy. Speciﬁc anti-GSTT1 antibodies
were associated with the development of hepatic acute
GVHD [15]. On the other hand, we have demonstrated T cell
activation after stimulation with GSTT1 peptides in GSTT1-
mismatched patients who underwent liver transplantation,UGT2B17
e Matched, % Mismatched, % P Value
27.2 (19.7-37.6) 56 (32.8-95.7) .033
57.9 44 .339
60 44 .202
¼ .033) are related to NRM after stem cell transplantation. OS is statistically
Figure 3. (A) NRM after 3 years was 52.6% for GSTT1-mismatched patients versus 26.8% for GSTT1-matched recipients (P ¼ .031); (B) GSTT1-mismatch condition is
related to a lower surveillance after allo-HSCT. Survival, 3 years after the transplantation, was 62% for GSTT1-matched versus 36.9% for mismatched patients (P ¼ .045).
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manuscript in preparation). Accordingly, these results indi-
cate that this drug-metabolizing enzymedconstitutively
expressed in the liver but highly induced under conditions of
stressdis able to induce both cellular and humoral responses
in liver transplantation.
Two reports from Riddell’s group described the presence
of CD8þ T cells reactive against UGT2B17 peptides in a single
mismatched patient who developed GVHD [18,19]. They
found that this enzyme is also expressed in antigen pre-
senting cells that were able to stimulate T cells in vitro [19].
Interestingly, it has been previously described that donor-
derived antigen presenting cells are able to induce cross-
presentation of host miHA, and effective cross-priming of
donor CD8þ T cells might trigger GVHD in other organs,
regardless of the preferential expression pattern of these
miHA [28,29]. For this reason, mismatch of miHA preferen-
tially expressed in hematopoietic tissue, which would
represent an ideal scenario to induce speciﬁc antileukemic
effect without GVHD, has not been translated into a better
survival in the clinical setting in most studies, as in addition
to graft-versus-leukemia, GVHD is also triggered against
other organs outside the hematopoietic tissue [30,31].
Several reports focusing on the role of mismatches on
either Y chromosomeeencoded antigens or hematopoietic
tissueerestricted antigens on GVHD and survival have been
published. A recent analysis on the role of 10 autosomal (HA-
1, HA-2, HA-3, HA-8, HB-1, ACC-1, ACC-2, SP110, PANE1,
UGT2B17) and 10 Y chromosomeeencoded miHA failed to
demonstrate any impact on outcome [32]. In this regard, we
found an effect of GSTT1 mismatch on both survival and risk
of GVHD. Concerning the latter, differences were highly sig-
niﬁcant between matched and mismatched patients for liver
GVHD, the organ of preferential expression of GSTT1. Similar
results were found regarding UGT2B12 disparity and gut
GVHD, the organ where UGT2B17 is highly expressed. At the
same time, both disparities also increased the risk of skin
GVHD. It could be hypothesized that other organs, although
to a lower extent, may also be targeted by allo-reactive T cells
after GVHD has been triggered.In conclusion, we demonstrated that the GSTT1mismatch
is a risk factor for both aGVHD and cGVHD, especially with
liver involvement. Moreover, GSTT1 disparity increases NRM
and hampers long-term survival. Considering the high rep-
resentation of the null allele in our population (20% homo-
zygous null), we can conclude that the GSTT1-antigen
disparity emerges as an important miHA, whose role in
donor selection should be further investigated.ACKNOWLEDGMENTS
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